{"corpus_id":498429,"paper_sha":"446de20062b1a21c61fb8046f472d380095feaef","doi":"10.4161/hv.20212","arxiv_id":null,"pmid":22485048,"pmcid":"3495724","mag_id":1989485865,"dblp_id":null,"acl_id":null,"title":"The investigational meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (ACWY-TT) and the seasonal influenza virus vaccine are immunogenic and well-tolerated when co-administered in adults","year":2012,"publication_date":"2012-04-09","venue":"Human Vaccines & Immunotherapeutics","journal":{"name":"Human Vaccines & Immunotherapeutics","pages":"881 - 887","volume":"8"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Journal Article","Randomized Controlled Trial","Research Support, Non-U.S. Gov't"],"s2_fields_of_study":["Medicine"],"reference_count":26,"citation_count":23,"influential_citation_count":1,"is_open_access":false,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Adolescent","mj":false,"ui":"D000293"},{"d":"Adult","mj":false,"ui":"D000328"},{"d":"Antibodies, Bacterial","mj":false,"qs":[{"q":"blood","mj":true,"ui":"Q000097"}],"ui":"D000907"},{"d":"Antibodies, Viral","mj":false,"qs":[{"q":"blood","mj":true,"ui":"Q000097"}],"ui":"D000914"},{"d":"Blood Bactericidal Activity","mj":false,"ui":"D001770"},{"d":"Drug-Related Side Effects and Adverse Reactions","mj":false,"qs":[{"q":"epidemiology","mj":true,"ui":"Q000453"}],"ui":"D064420"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"Hemagglutination Inhibition Tests","mj":false,"ui":"D006385"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Influenza Vaccines","mj":false,"qs":[{"q":"administration & dosage","mj":false,"ui":"Q000008"},{"q":"adverse effects","mj":true,"ui":"Q000009"},{"q":"immunology","mj":true,"ui":"Q000276"}],"ui":"D007252"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Meningococcal Vaccines","mj":false,"qs":[{"q":"administration & dosage","mj":false,"ui":"Q000008"},{"q":"adverse effects","mj":true,"ui":"Q000009"},{"q":"immunology","mj":true,"ui":"Q000276"}],"ui":"D022401"},{"d":"Middle Aged","mj":false,"ui":"D008875"},{"d":"Young Adult","mj":false,"ui":"D055815"}],"chemicals":[{"n":"Antibodies, Bacterial","ui":"D000907","reg":"0"},{"n":"Antibodies, Viral","ui":"D000914","reg":"0"},{"n":"Influenza Vaccines","ui":"D007252","reg":"0"},{"n":"Meningococcal Vaccines","ui":"D022401","reg":"0"},{"n":"tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine","ui":"C576777","reg":"0"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":null,"s2_open_access_landing_url":null,"s2_open_access_license":null,"s2_open_access_status":null,"pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"Co-administration of meningococcal serogroups A, C, W-135 and Y conjugate vaccine (ACWY-TT) with seasonal influenza vaccine was investigated in a subset of adults enrolled in a larger study evaluating lot-to-lot consistency of ACWY-TT and non-inferiority to licensed tetravalent meningococcal polysaccharide vaccine (MenPS). Subjects in this sub-study were randomized (3:1:1) to receive ACWY-TT alone (ACWY-TT group) or with seasonal influenza vaccine (Coad), or licensed MenPS alone. Serum bactericidal antibodies (rSBA) and serum haemagglutination-inhibition (HI) antibody titers were measured pre- and 1 mo post-vaccination. Non-inferiority of the Coad group compared with ACWY-TT group was demonstrated in terms of rSBA geometric mean antibody titers (GMTs) to serogroups A, W-135 and Y. For serogroup C the pre-defined non-inferiority limit was marginally exceeded. Post-vaccination rSBA GMTs were significantly higher (exploratory analysis) in the Coad group compared with the MenPS group for serogroups A, W-135, and Y and were similar to the MenPS group for serogroup C. Overall, > 97% of subjects achieved rSBA titers ≥ 1:128 for all serogroups. The Coad group met all criteria defined by the Committee on Human Medicinal Products (CHMP) for seroprotection, seroconversion and seroconversion factor for HI antibodies for all three influenza strains. Grade 3 solicited local/general symptoms were reported by ≤ 1.9% of subjects in any group. These data support the co-administration of ACWY-TT with seasonal influenza vaccine when protection is needed against both diseases. This study is registered at clinicaltrials.gov NCT00453986","claims":[{"public_id":"cl_d9502b7708abb6893542373be3f4af86","status":"active","text":"Co-administration of ACWY-TT with seasonal influenza vaccine is immunogenic in adults, meeting CHMP criteria for hemagglutination-inhibition antibody seroprotection, seroconversion, and seroconversion factor for all three influenza strains.","confidence":0.98,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_d9502b7708abb6893542373be3f4af86"},{"public_id":"cl_bc9346367cd117b06e65bde3e0862b0b","status":"active","text":"Co-administration of ACWY-TT with seasonal influenza vaccine is non-inferior to ACWY-TT alone for serum bactericidal antibody geometric mean titers to serogroups A, W-135, and Y.","confidence":0.96,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_bc9346367cd117b06e65bde3e0862b0b"},{"public_id":"cl_290983cd48b588d92e110764d6aa259a","status":"active","text":"Grade 3 solicited local or general symptoms were rare, occurring in no more than 1.9% of subjects in any group.","confidence":0.94,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_290983cd48b588d92e110764d6aa259a"},{"public_id":"cl_67841f288a18db4a7916c3d66a42e1c1","status":"active","text":"More than 97% of subjects achieved serum bactericidal antibody titers of at least 1:128 for all meningococcal serogroups after vaccination.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_67841f288a18db4a7916c3d66a42e1c1"},{"public_id":"cl_89776bd9c413ef95f211687a271959bc","status":"active","text":"The non-inferiority limit was marginally exceeded for serogroup C when co-administered with seasonal influenza vaccine.","confidence":0.92,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_89776bd9c413ef95f211687a271959bc"}],"concepts":[{"public_id":"co_1a8609f1f00561d5f9d2e08ca772c355","status":"active","name":"non-inferiority","description":"An evaluation criterion indicating that one intervention is not unacceptably worse than a comparator.","types":["statistical criterion"],"aliases":["non-inferior"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_1a8609f1f00561d5f9d2e08ca772c355"},{"public_id":"co_1be86a057eddf1b41cd67b17f70e2d37","status":"active","name":"hemagglutination-inhibition antibody titers","description":"Antibody titers measured by hemagglutination-inhibition assay against influenza antigens.","types":["immunologic measure"],"aliases":["HI antibody titers","HI"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_1be86a057eddf1b41cd67b17f70e2d37"},{"public_id":"co_4fbff49653d59b92ce2575451faa2611","status":"active","name":"meningococcal serogroups A, C, W-135 and Y","description":"The four meningococcal serogroups included in the quadrivalent conjugate vaccine.","types":["biological grouping"],"aliases":["ACWY","A, C, W-135 and Y"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_4fbff49653d59b92ce2575451faa2611"},{"public_id":"co_5803ecf25f0bc1126197a174c8e36189","status":"active","name":"serogroup A","description":"One of the meningococcal serogroups targeted by the ACWY-TT vaccine.","types":["meningococcal serogroup"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_5803ecf25f0bc1126197a174c8e36189"},{"public_id":"co_5c8c2a036ba21708a43279c9f79dcee8","status":"active","name":"ACWY-TT","description":"A tetanus toxoid-conjugated meningococcal vaccine targeting serogroups A, C, W-135, and Y.","types":["vaccine"],"aliases":["meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_5c8c2a036ba21708a43279c9f79dcee8"},{"public_id":"co_6595c592fbe0b852c2c5b281ba8c375b","status":"active","name":"adults","description":"Adult participants enrolled in the vaccination sub-study.","types":["population"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_6595c592fbe0b852c2c5b281ba8c375b"},{"public_id":"co_775dd41e9d3231bbd27f0eb30e3977ea","status":"active","name":"serogroup W-135","description":"One of the meningococcal serogroups targeted by the ACWY-TT vaccine.","types":["meningococcal serogroup"],"aliases":["W-135"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_775dd41e9d3231bbd27f0eb30e3977ea"},{"public_id":"co_776e035d7f32232ef02dfa7162f49a2c","status":"active","name":"grade 3 solicited local/general symptoms","description":"Severe local or systemic adverse reactions actively solicited after vaccination.","types":["adverse event"],"aliases":["grade 3 symptoms"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_776e035d7f32232ef02dfa7162f49a2c"},{"public_id":"co_9df7992215aa94400b9ade15fb888cd0","status":"active","name":"rSBA titers","description":"Serum bactericidal antibody titers reported as reciprocal dilution values.","types":["immunologic measure"],"aliases":["serum bactericidal antibody titers"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_9df7992215aa94400b9ade15fb888cd0"},{"public_id":"co_bf819e43d7a9c74fd234da9b69e5bfda","status":"active","name":"serogroup Y","description":"One of the meningococcal serogroups targeted by the ACWY-TT vaccine.","types":["meningococcal serogroup"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_bf819e43d7a9c74fd234da9b69e5bfda"},{"public_id":"co_c6bad6f5599f7584dfe65cb4b857fda5","status":"active","name":"serum bactericidal antibodies","description":"Functional antibodies measured by serum bactericidal activity against meningococcal serogroups.","types":["immunologic measure"],"aliases":["rSBA"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_c6bad6f5599f7584dfe65cb4b857fda5"},{"public_id":"co_dc0bd9f28d1444697b7c188da19a5866","status":"active","name":"serogroup C","description":"One of the meningococcal serogroups targeted by the ACWY-TT vaccine.","types":["meningococcal serogroup"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_dc0bd9f28d1444697b7c188da19a5866"},{"public_id":"co_ed1753d8381853f8984e245925786aaa","status":"active","name":"seasonal influenza vaccine","description":"A vaccine administered to protect against circulating seasonal influenza virus strains.","types":["vaccine"],"aliases":["influenza vaccine"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_ed1753d8381853f8984e245925786aaa"}],"external_ids":{"DOI":"10.4161/hv.20212","ArXiv":null,"PubMed":22485048,"PubMedCentral":"3495724","MAG":1989485865,"DBLP":null,"ACL":null},"open_access":{"is_open_access":false,"pdf_url":null,"landing_url":"https://sah.borca.ai/papers/498429","source":null,"pdf_url_source":null,"license":null,"reason":"pdf_url_not_indexed"},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":630682,"paper_uid":"a4540c26-49b0-47d3-9b6f-6e4fa9eda573","canonical_identity":{"paper_id":630682,"paper_uid":"a4540c26-49b0-47d3-9b6f-6e4fa9eda573","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/498429"}